GVAX
GVAX is a pharmaceutical drug with 10 clinical trials. Currently 1 active trials ongoing. Historical success rate of 77.8%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
77.8%
7 of 9 finished
22.2%
2 ended early
1
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Pilot Study of GVAX in Colorectal Cancer Cells
GVAX vs. Placebo for MDS/AML After Allo HSCT
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Clinical Trials (10)
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Pilot Study of GVAX in Colorectal Cancer Cells
GVAX vs. Placebo for MDS/AML After Allo HSCT
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10